SABCS 2022 Conference Coverage
Playback speed
10 seconds
SABCS 2022 Results From a Pre-Planned monarchE OS Interim Analysis, Including 4-Year Efficacy Outcomes: Abemaciclib + ET for HR+/HER2-/N+ High-Risk EBC
By
SABCS 2022 Conference Coverage
FEATURING
Jens Huober
By
SABCS 2022 Conference Coverage
FEATURING
Jens Huober
284 views
January 30, 2023
Comments 0
Login to view comments.
Click here to Login
Videos